JP6153470B2 - 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 - Google Patents

糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 Download PDF

Info

Publication number
JP6153470B2
JP6153470B2 JP2013536471A JP2013536471A JP6153470B2 JP 6153470 B2 JP6153470 B2 JP 6153470B2 JP 2013536471 A JP2013536471 A JP 2013536471A JP 2013536471 A JP2013536471 A JP 2013536471A JP 6153470 B2 JP6153470 B2 JP 6153470B2
Authority
JP
Japan
Prior art keywords
fmoc
group
glycosylated polypeptide
sugar chain
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013536471A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013047846A1 (ja
Inventor
泉 坂本
泉 坂本
一博 深江
一博 深江
克成 手塚
克成 手塚
圭亮 田鶴
圭亮 田鶴
政敏 前田
政敏 前田
康宏 梶原
康宏 梶原
孝 辻
孝 辻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glytech Inc
Original Assignee
Glytech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glytech Inc filed Critical Glytech Inc
Publication of JPWO2013047846A1 publication Critical patent/JPWO2013047846A1/ja
Application granted granted Critical
Publication of JP6153470B2 publication Critical patent/JP6153470B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013536471A 2011-10-01 2012-09-28 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 Expired - Fee Related JP6153470B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011218793 2011-10-01
JP2011218793 2011-10-01
PCT/JP2012/075262 WO2013047846A1 (ja) 2011-10-01 2012-09-28 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2013047846A1 JPWO2013047846A1 (ja) 2015-03-30
JP6153470B2 true JP6153470B2 (ja) 2017-06-28

Family

ID=47995870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013536471A Expired - Fee Related JP6153470B2 (ja) 2011-10-01 2012-09-28 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Country Status (16)

Country Link
US (1) US10358470B2 (https=)
EP (1) EP2762489B1 (https=)
JP (1) JP6153470B2 (https=)
KR (1) KR101979045B1 (https=)
CN (2) CN109134642A (https=)
AU (1) AU2012317325B2 (https=)
BR (1) BR112014007766B1 (https=)
CA (1) CA2850469C (https=)
DK (1) DK2762489T3 (https=)
IN (1) IN2014CN02982A (https=)
MY (1) MY168902A (https=)
PH (1) PH12014500694B1 (https=)
RU (1) RU2636456C2 (https=)
SG (2) SG11201401071YA (https=)
TW (1) TWI633115B (https=)
WO (1) WO2013047846A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2762489T3 (en) 2011-10-01 2018-07-02 Glytech Inc GLYCOSYLED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
SG11201507769SA (en) * 2013-03-29 2015-10-29 Glytech Inc Polypeptide having sialylated sugar chains attached thereto
CN114685645B (zh) * 2020-12-30 2025-03-21 深圳翰宇药业股份有限公司 一种索玛鲁肽的合成方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
EE05214B1 (et) * 1998-04-28 2009-10-15 Applied Research Systems ARS Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
BR9915548A (pt) * 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
EP1240327B1 (en) * 1999-12-08 2008-02-06 Amgen Inc., Interferon-like molecules and uses thereof
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
KR20030057529A (ko) 2000-09-08 2003-07-04 그리폰 테라퓨틱스, 인코포레이티드 합성 적혈구생성 자극 단백질
WO2002074806A2 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
BR0208041A (pt) 2001-03-15 2004-02-25 Merck Patent Gmbh Interferon beta modificado com imunogenicidade reduzida
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
ES2411007T3 (es) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
AU2002358181A1 (en) 2001-12-11 2003-07-09 Aventis Pasteur Mutated hiv tat
US20060083715A1 (en) * 2002-03-12 2006-04-20 Steven Glazer Interferon beta-like molecules for treatment of stroke
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
JP2006513990A (ja) * 2002-09-27 2006-04-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド インターフェロンβを用いる慢性炎症性脱髄性多発性ニューロパシーの治療
EP1581631A4 (en) 2002-10-01 2007-09-05 Xencor Inc INTERFERON VARIANTS HAVING IMPROVED PROPERTIES
KR100876518B1 (ko) 2002-12-26 2008-12-31 오츠카 가가쿠 가부시키가이샤 당사슬 아스파라긴 유도체 및 그의 제조방법
AU2004266969B2 (en) 2003-08-25 2010-02-25 Taniguchi, Tadatsugu Interferon-beta composite
US20090214472A1 (en) 2004-03-01 2009-08-27 Enzon Pharmaceuticals Inc. Interferon-beta polymer conjugates
RU2392963C2 (ru) * 2004-08-09 2010-06-27 Элиоз Байофарма, Инк. Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
WO2006020580A2 (en) 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
KR100781666B1 (ko) 2004-11-02 2007-12-03 신영기 인간 인터페론-베타 변이체
WO2007022799A1 (en) * 2005-08-26 2007-03-01 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
KR20100049032A (ko) * 2007-06-19 2010-05-11 오츠카 가가쿠 가부시키가이샤 당사슬 부가 glp―1 펩티드
CA2694542C (en) 2007-07-31 2017-08-29 Otsuka Chemical Co., Ltd. Method for producing peptide
JP2009242372A (ja) 2008-03-11 2009-10-22 Yokohama City Univ 均一な糖鎖構造を有するエリスロポエチン誘導体
US8765669B2 (en) 2008-06-17 2014-07-01 Glytech, Inc. Glycosylated GLP-1 peptide
CA2733362C (en) * 2008-08-08 2016-10-18 Universiteit Gent Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof
HUE037238T2 (hu) * 2008-08-19 2018-08-28 Glytech Inc Glikoprotein elõállítási eljárás és screening eljárás
WO2012051615A1 (en) 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
RU2586524C2 (ru) 2011-03-10 2016-06-10 Глитек, Инк. Способ получения гликопептида, имеющего сиалированную сахарную цепь, и способ получения производного сиалилгликоаспарагина
WO2013002330A1 (ja) 2011-06-29 2013-01-03 協和発酵キリン株式会社 たん白質の精製方法
DK2762489T3 (en) 2011-10-01 2018-07-02 Glytech Inc GLYCOSYLED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Also Published As

Publication number Publication date
CA2850469A1 (en) 2013-04-04
DK2762489T3 (en) 2018-07-02
TW201321404A (zh) 2013-06-01
SG11201401071YA (en) 2014-08-28
CN104080803A (zh) 2014-10-01
TWI633115B (zh) 2018-08-21
AU2012317325B2 (en) 2016-10-06
AU2012317325A1 (en) 2014-04-17
BR112014007766A2 (pt) 2017-04-04
EP2762489B1 (en) 2018-03-28
IN2014CN02982A (https=) 2015-07-03
SG10201602076QA (en) 2016-04-28
CA2850469C (en) 2020-07-07
PH12014500694A1 (en) 2014-05-12
MY168902A (en) 2018-12-04
EP2762489A9 (en) 2015-02-11
KR101979045B1 (ko) 2019-05-15
PH12014500694B1 (en) 2020-01-31
RU2636456C2 (ru) 2017-11-23
EP2762489A1 (en) 2014-08-06
WO2013047846A1 (ja) 2013-04-04
CN104080803B (zh) 2020-08-04
US20140369964A1 (en) 2014-12-18
KR20140095051A (ko) 2014-07-31
JPWO2013047846A1 (ja) 2015-03-30
RU2014116550A (ru) 2015-10-27
US10358470B2 (en) 2019-07-23
EP2762489A4 (en) 2015-05-06
BR112014007766B1 (pt) 2022-05-10
CN109134642A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
JP5517620B2 (ja) ペプチドの製造方法
JP5925760B2 (ja) シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド
KR20150102009A (ko) 당쇄 부가 링커, 당쇄 부가 링커와 생리 활성 물질을 포함하는 화합물 또는 그 염, 및 그것들의 제조 방법
US20120114595A1 (en) Sugar chain-added ailim extracellular domain and method for producing same
JP6153470B2 (ja) 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
DK2982686T3 (en) POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170530

R150 Certificate of patent or registration of utility model

Ref document number: 6153470

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees